How different types of interferons help protect against respiratory viruses
Interplay between canonical and non-canonical interferons in defense against respiratory viruses
This study is looking at how a special protein called IFN epsilon helps protect our lungs from viruses like COVID-19 and the flu, and it hopes to find new ways to improve treatments for asthma and other lung issues.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-11119021 on NIH RePORTER |
What this research studies
This research investigates the role of various interferons, particularly a lesser-known type called IFN epsilon, in defending the respiratory system against viruses like SARS-CoV-2 and influenza. It aims to understand how these interferons are produced in the airway and how they can stimulate antiviral responses. By studying the balance between different interferons, the research seeks to uncover new insights into how the body responds to respiratory infections and the potential implications for treating conditions like asthma and chronic lung disease.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with respiratory conditions such as asthma or COPD, as well as those who have been affected by respiratory viruses.
Not a fit: Patients with non-respiratory conditions or those who do not have a history of respiratory viral infections may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatments for respiratory viral infections and better management of chronic lung diseases.
How similar studies have performed: While the role of canonical interferons is well-established, the investigation of IFN epsilon in the respiratory tract is relatively novel and has not been extensively studied.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Foxman, Ellen Flescher — Yale University
- Study coordinator: Foxman, Ellen Flescher
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.